AstraZeneca’s RSV Antibody May Need More Data Due To Impact Of Maternal Vaccines

 
• By Derrick Gingery

Maternal vaccines may cause first RSV infections to occur when infants are older, requiring increased study of disease patterns and additional dosing data on AstraZeneca/Sanofi’s nirsevimab in older babies. 

maternal vaccine
Children may not need a nirsevimab dose as early as thought if maternal RSV vaccines are introduced. • Source: Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews